Clinical trials: Polycystic Kidney
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance…
- Trial name
- HIYA-PKD (NCT07260071)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- King's College London
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD…
- Trial name
- ESSENTIAL (NCT03949894)
- Testing
- Tolvaptan
- Where
- 18 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are…
- Trial name
- AGAINST-PLD (NCT05478083)
- Testing
- Leuprorelin
- Where
- 2 sites in Netherlands
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Polycystic Kidney, Autosomal Dominant, Chronic Kidney Diseases
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
The ability to concentrate and dilute urine is primarily regulated via vasopressin (AVP) dependent Aquaporin-2 water channels (AQP2 channels) in the kidney's collecting duct.
- Trial name
- POVA (NCT04363554)
- Testing
- Fluid intake, Thirsting
- Where
- Denmark
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
ADPKD
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder occurring in 1:400-1:1.000 live births and affects 4 to 6 million persons worldwide and about 205.000 people in Europe (EU).
- Trial name
- METROPOLIS (NCT03764605)
- Testing
- Metformin, Tolvaptan
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Polycystic Liver Disease, Polycystic Kidney, Autosomal Dominant
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by >20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic…
- Trial name
- CURSOR (NCT02021110)
- Testing
- Ursodeoxycholic Acid
- Where
- 3 sites in Netherlands, Spain
- Volunteers
- 34 people
- Sponsor
- Radboud University Medical Center
Autosomal Dominant Polycystic Kidney Disease
Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
The general aim of the trial is to assess the efficacy of one year treatment with long-acting somatostatin analogue (Octreotide LAR) compared with placebo in slowing kidney and liver growth rate in patients with ADPKD and…
- Trial name
- ALADIN2 (NCT01377246)
- Testing
- Octreotide-LAR, Saline solution.
- Where
- 6 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
ADPKD, Pain
Somatosensory Phenotyping of ADPKD
Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their…
- Trial name
- NCT06970028
- Testing
- Quantitative Sensory Testing, Questionnaires regarding pain and quality of life
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Polycystic Kidney Disease, Adult, ADPKD
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy of lixivaptan in participants who previously experienced liver chemistry test abnormalities while treated with…
- Trial name
- ALERT (NCT04152837)
- Testing
- Lixivaptan
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Palladio Biosciences
Autosomal Dominant Polycystic Kidney Disease
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.
- Trial name
- NCT01336972
- Testing
- Tolvaptan
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Polycystic Liver Disease
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
This Pilot study will enable development \& assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q).
- Trial name
- NCT02173080
- Testing
- PLD-Q
- Where
- United States
- Volunteers
- 594 people
- Sponsor
- Mayo Clinic
Polycystic Kidney, Autosomal Dominant
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02494141
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
- Trial name
- NCT07022119
- Testing
- VX-407
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Polycystic Kidney, Autosomal Dominant
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02251275
- Testing
- Tolvaptan
- Where
- 210 sites in United States, Argentina and 18 more
- Volunteers
- 1,803 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autosomal Dominant Polycystic Kidney Disease
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
The Division of Kidney Urology and Hematology Disease (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) funded a cooperative agreement (UO1) for a consortium of participating clinical centers…
- Trial name
- CRISP II (NCT01039987)
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- University of Pittsburgh
Autosomal Dominant Polycystic Kidney
Outcome of ADPKD With Octreotide LAR
In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other…
- Trial name
- ADPKD648 (NCT06193616)
- Testing
- Octreotide
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease （ADPKD)
A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).
- Trial name
- NCT01280721
- Testing
- tolvaptan
- Where
- 7 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Polycystic Kidney Disease
Polycystic Kidney Disease Data Repository
Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide.
- Trial name
- NCT00792155
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- The Rogosin Institute
Kidney Diseases
Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutations in the PKD1 or PKD2 genes, which encode polycystins 1 and 2.
- Trial name
- ETERNAL-PKD (NCT06291116)
- Testing
- standard care + rotigotine at 4 mg/24h for 24 months., standard care for 24 months.
- Where
- 4 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Rouen